Pulmonary Disease, Chronic ObstructivePhase 1NCT01762774

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers

A Phase 1 study testing GSK2256294 in people with Pulmonary Disease, Chronic Obstructive, run by GlaxoSmithKline at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 55 years, men onlyHealthy volunteers can take part
Conditions the study is for: Pulmonary Disease, Chronic Obstructive
What is being tested?: GSK2256294
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 56 participants
Where: 1 siteUnited Kingdom
Study dates: 16 Jan 2013to 1 May 2014
Phase: Phase 1
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 55 years
Men only
Healthy volunteers accepted
Adult

Who may be able to join

Suitable for cannulation and with adequate venous access.
12 lead ECG without any clinically significant abnormality as judged by the Investigator, and ECGs QTcF (QT interval was corrected using Fridericia's formula)<=450 milliseconds (msec) determined by the average of triplicate ECGs.
Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter outside the reference range for the population being studied may be included only if the Investigator agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Consultation with the medical monitor is required.
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
Male between 18 and 55 years of age inclusive, at the time of signing the informed consent.
Male subjects must agree to use one of the approved contraception methods This criterion must be followed from the time of the first dose of study medication until the follow-up visit.

Show all 10Show fewer

Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
For Cohort 1 Only: Subjects should have blood pressure (BP) <=130/80; body weight >=60 kilograms (kg) and body mass index (BMI) within the range 19 to 25 kilogram/meter squared (kg/m^2) (inclusive); subjects should be non-smokers, which for this study is defined as having smoked <100 cigarettes or <1 pack per year in their lifetime.
For Cohorts 2 to 4 Only: Subjects must have smoked in the 12 month period preceding the screening visit. Smoking is defined as >=10 cigarettes/day for at least the preceding 1 year, and have a >5-pack year history. [number of pack years = (number of cigarettes per day/20) x number of years smoked]; having body weight >=60 kg and BMI within the range 28 to 35 kg/m^2 (inclusive); and BP <=140/90.
Cohorts 3 and 4 Only: Palpable brachial artery in the non-dominant and/or dominant hands, as assessed by a clinician at screening.

Who cannot join

Subjects with any history of a carcinoma.
Participants who have had previous vasovagal events secondary to any painful stimulus e.g. venepuncture or have a phobia of blood.
Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
Significant cardiac, pulmonary, metabolic, renal, gastrointestinal or other conditions that in the opinion of the investigator and/or GlaxoSmithKline (GSK) medical monitor, places the subject at an unacceptable risk as participant in this trial. Patients with asthma or diabetes are excluded.
A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody at screening.
A positive pre-study drug/alcohol screen.

Show all 15Show fewer

A positive test for HIV antibody.
History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males. One unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
The use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator or GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. Other concomitant medication may be considered on a case by case basis by the GSK Medical Monitor.
History of sensitivity to any of the study medications and challenge agents, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
For Cohorts 2 to 4 Only: Smokers who require a cigarette within 30 minutes after they wake in the morning, or cannot abstain from smoking for approximately 5 hours; or subjects with symptomatic asthma requiring regular inhaled or oral steroids and bronchodilators.; or subjects who are currently on statins or have been on statins within 3 months prior to the first dose of study medication.
For Cohorts 3 and 4 Only: Subjects who are unable to lie still for the duration of the forearm study (up to 3 hours).

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site

GSK Investigational Site
Cambridge, CB2 2GG

Other trials in United Kingdom

About this study

Official title: A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers

This study is the First Time in Human Study for GSK2256294 and will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of GSK2256294 administered to healthy male volunteers (Cohort 1) and otherwise healthy adult male moderately obese smokers (Cohorts 2 to 4). Cohorts 1 and 2 will enrol 12 subjects each and each subject will take part in four study periods. All subjects will receive placebo regimen and three dosing regimens of GSK2256294 in a specified sequence (planned doses 2 mg, 6 mg and 18 mg in Cohort 1 and 15 mg, 40 mg and 100 mg in Cohort 2). Each study period will be followed by a Wash-out period of 7 to 14 days in Cohort 1 and up to 4 weeks in Cohort 2. During each study period subjects will be in-house from Day -1 until the 48 hours post dose assessments have been completed. Subjects will return to the unit as out-patients for remaining post-dose assessments. Subjects will then be followed for 7 to 14 days in Cohort 1 and up to 3 to 4 weeks in Cohort 2. Total duration of the study for Cohort 1 will be 98 days and for Cohort 2 it will be up to 144 days. Cohort 3 and 4 will each recruit 15 subjects. For Cohorts 3 and 4, each subject will take part in one treatment period of 18 days (Day-1 to Day 17) with dosing from Day 1 to Day 14. Subjects will then be followed for 7 to 14 days. Total duration of the study for Cohort 3 and Cohort 4 will be 67 days. Dose selection for Cohorts 3 and 4 will be based on the safety, PK profile and enzyme inhibition obtained in Cohorts 1 and 2. This study will also evaluate the evidence for a functional effect of soluble Epoxide Hydrolase (sEH) in a forearm blood flow (FBF) model.

Conditions: Pulmonary Disease, Chronic Obstructive
Being tested: GSK2256294, Placebo
Keywords: COPD, forearm blood flow, soluble Epoxide Hydrolase inhibitor
Medical subject headings: Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

GSK2256294Drug
GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
PlaceboDrug
Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).

Study groups in NCT01762774
Study group	Role	What they receive
Cohort 1	Experimental	Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules. Receives: Drug: GSK2256294; Drug: Placebo
Cohort 2	Experimental	Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules. Receives: Drug: GSK2256294; Drug: Placebo
Cohort 3	Experimental	Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2. Receives: Drug: GSK2256294; Drug: Placebo
Cohort 4	Experimental	Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3. Receives: Drug: GSK2256294; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Safety of single oral doses of GSK2256294 assessed by clinical monitoring of vital signs (Cohort 1).
Vital signs include systolic blood pressure, diastolic blood pressure, and pulse rate. Vital signs will be collected with the subject semi-supine and after they have been resting for 5 minutes.
Measured: Up to 98 days.
Safety of single oral doses of GSK2256294 assessed by clinical monitoring of vital signs (Cohort 2).
Vital signs include systolic blood pressure, diastolic blood pressure, and pulse rate. Vital signs will be collected with the subject semi-supine and after they have been resting for 5 minutes.
Measured: Up to 144 days.
Safety of single oral doses of GSK2256294 assessed by clinical monitoring of Electrocardiogram (Cohort 1).
12-lead electrocardiograms (ECGs) will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be obtained in the semi-supine position after the subject has been resting for at least 5 minutes.
Measured: Up to 98 days.
Safety of single oral doses of GSK2256294 assessed by clinical monitoring of Electrocardiogram (Cohort 2).
12-lead electrocardiograms (ECGs) will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be obtained in the semi-supine position after the subject has been resting for at least 5 minutes.
Measured: Up to 144 days.
Safety of repeat oral doses of GSK2256294 assessed by clinical monitoring of vital signs (Cohort 3 and 4).
Vital signs include systolic blood pressure, diastolic blood pressure, and pulse rate. Vital signs will be collected with the subject semi-supine and after they have been resting for 5 minutes.
Measured: Up to 67 days
Safety of repeat oral doses of GSK2256294 assessed by clinical monitoring ECG (Cohort 3 and 4).
12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be obtained in the semi-supine position after the subject has been resting for at least 5 minutes.
Measured: Up to 67 days.
Safety of single oral doses of GSK2256294 assessed by clinical laboratory assessments (Cohort 1 ).
Safety data will include assessments of clinical laboratory tests (hematology, clinical chemistry and urinalysis).
Measured: Up to 98 days.
Safety of single oral doses of GSK2256294 assessed by clinical laboratory assessments (Cohort 2).
Safety data will include assessments of clinical laboratory tests (hematology, clinical chemistry and urinalysis).
Measured: Up to 144 days.
Safety of repeat oral doses of GSK2256294 assessed by clinical laboratory assessments (Cohort 3 and 4).
Safety data will include assessments of clinical laboratory tests (hematology, clinical chemistry and urinalysis).
Measured: Up to 67 days.
Safety of single oral doses of GSK2256294 assessed by number of participants with adverse events (Cohort 1).
Adverse events (AEs) will be recorded from the start of Study Treatment until the follow-up contact.
Measured: Up to 98 days.
Safety of single oral doses of GSK2256294 assessed by number of participants with adverse events (Cohort 2).
AEs will be recorded from the start of Study Treatment until the follow-up contact.
Measured: Up to 144 days.
Safety of repeat oral doses of GSK2256294 assessed by number of participants with adverse events (Cohort 3 and 4).
AEs will be recorded from the start of Study Treatment until the follow-up contact.
Measured: Up to 67 days.

Secondary outcomes (7)

Composite of PK parameters following single dose of GSK2256294.
PK parameters include: maximum observed plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC [0-t]) and from time zero extrapolated to infinite time (AUC[0-infinity]), apparent terminal phase half-life (t1/2). AUC (0-infinity) or area under the concentration-time curve over the dosing interval (AUC[0-tau]) and Cmax following single and repeat doses may be used for assessment of dose proportionality.
Measured: PK samples will be collected at pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours post dose in each treatment period.
Composite of PK parameters following repeat doses of GSK2256294.
PK parameters include: Cmax, tmax, (AUC [0-t]), (AUC [0-infinity]), (t1/2). AUC (0-infinity) or (AUC [0-tau]) and Cmax following single and repeat doses may be used for assessment of dose proportionality. Trough concentration (Ctau) samples collected on the specified days may be used to assess attainment of steady state.
Measured: Up to Day 17 in Cohort 3 and 4
Percent inhibition of sEH enzyme activity in whole blood after single oral dose of GSK2256294 as a measure of PD effect.
Percent inhibition of soluble sEH enzyme activity in whole blood will be measured from plasma samples. GSK2256294 is a potent and reversible inhibitor of sEH and this will be evaluated to determine the PD effect of GSK2256294 on sEH enzyme activity.
Measured: Plasma samples will be collected at pre-dose, 1, 2, 6, 8, 12, 24, 48, and 72 hours post dose in Cohort 1 and 2.
Percent inhibition of sEH enzyme activity and Leukotoxin : leukotoxin-diol ratio in plasma after repeat oral doses of GSK2256294 .
The PD inhibitory effect of repeat oral doses of GSK2256294 on sEH inhibition in the study population will be investigated via the sEH enzyme inhibition assay and the ratio of leukotoxin to leukotoxin diol data subject to data available from the study. Samples will be collected to measure sEH enzyme inhibition and the ratio of substrate to product for biomarkers: leukotoxin: leukotoxin diol ratio
Measured: Up to Day 17 in Cohort 3 and 4
Exposure-response relationship between the blood concentration of GSK2256294 and sEH enzyme inhibition, leukotoxin : leukotoxin-diol ratio (if data permit) following single dose of GSK2256294.
Based on the availability of data, a PK/PD model will be attempted to explain the dose response (exposure response) relationship between GSK2256294 and the various biomarkers analyzed in the study.
Measured: Plasma samples will be collected at pre-dose, 1, 2, 6, 8, 12, 24, 48, and 72 hours post dose in cohort 1 and 2.
Exposure-response relationship between the blood concentration of GSK2256294 and sEH enzyme inhibition, leukotoxin : leukotoxin-diol ratio (if data permit) following repeat doses of GSK2256294.
Based on the availability of data, a PK/PD model will be attempted to explain the dose response (exposure response) relationship between GSK2256294 and the various biomarkers analyzed in the study.
Measured: Up to Day 17 in cohort 3 and 4.
Change from baseline forearm blood flow relative to the preceding challenge agent, as measured by venous occlusion plethysmography.
A plethysmograph is an instrument for measuring changes in volume within an organ or whole body (usually resulting from fluctuations in the amount of blood or air it contains). It will be used to determine the effects of GSK2256294 and placebo on endothelium-dependent and independent vasodilatation.
Measured: Baseline (screening) and Day 1 and Day 14 in Cohort 3 and 4.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

16 Jan 20131 May 2014

First posted8 Jan 2013 (estimated)
Study start16 Jan 2013
Primary completion1 May 2014
Study completion1 May 2014

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (2)Papers the sponsor has linked to this study.
Other trials for Pulmonary Disease, Chronic ObstructiveStudies of the same condition, open and under way.
More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Single group
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 56 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01762774
Sponsor's protocol ID: 114068
Status last verified: May 2017
First submitted: 13 Dec 2012
Last updated: 9 May 2017
Results posted: No
Data monitoring committee: No
Individual data sharing: Yes: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Publications

Yang L, Cheriyan J, Gutterman DD, Mayer RJ, Ament Z, Griffin JL, Lazaar AL, Newby DE, Tal-Singer R, Wilkinson IB. Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. Chest. 2017 Mar;151(3):555-563. doi: 10.1016/j.chest.2016.10.058. Epub 2016 Nov 21.
PubMed 27884766
Lazaar AL, Yang L, Boardley RL, Goyal NS, Robertson J, Baldwin SJ, Newby DE, Wilkinson IB, Tal-Singer R, Mayer RJ, Cheriyan J. Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. Br J Clin Pharmacol. 2016 May;81(5):971-9. doi: 10.1111/bcp.12855. Epub 2016 Jan 17.
PubMed 26620151

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease

All Pulmonary Disease, Chronic Obstructive trials

Study at a glance

From the registry record, last updated by the sponsor on 9 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers
ClinicalTrials.gov ID: NCT01762774
Acronym / sponsor ID: 114068
Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: COPD, forearm blood flow, soluble Epoxide Hydrolase inhibitor
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 56 participants (actual)
Lead sponsor: GlaxoSmithKlineIndustry (pharma, biotech, devices)
Study start: 16 Jan 2013 (actual)
Primary completion: 1 May 2014 (actual)
Study completion: 1 May 2014 (actual)
First posted: 8 Jan 2013 (estimated)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Single group
Masking: Double blind (participant, investigator)
Number of arms: 4

Arm	Type	Receives
Cohort 1	Experimental	Drug: GSK2256294, Drug: PlaceboHealthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
Cohort 2	Experimental	Drug: GSK2256294, Drug: PlaceboObese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
Cohort 3	Experimental	Drug: GSK2256294, Drug: PlaceboObese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
Cohort 4	Experimental	Drug: GSK2256294, Drug: PlaceboObese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.

Who may qualify

Ages: 18 to 55 years
Sex: Male only
Healthy volunteers: Accepted
Age groups: Adult

Key inclusion criteria (10 listed)

Suitable for cannulation and with adequate venous access.
12 lead ECG without any clinically significant abnormality as judged by the Investigator, and ECGs QTcF (QT interval was corrected using Fridericia's formula)<=450 milliseconds (msec) determined by the average of triplicate ECGs.
Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter outside the reference range for the population being studied may be included only if the Investigator agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Consultation with the medical monitor is required.
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
Male between 18 and 55 years of age inclusive, at the time of signing the informed consent.

Key exclusion criteria (15 listed)

Subjects with any history of a carcinoma.
Participants who have had previous vasovagal events secondary to any painful stimulus e.g. venepuncture or have a phobia of blood.
Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
Significant cardiac, pulmonary, metabolic, renal, gastrointestinal or other conditions that in the opinion of the investigator and/or GlaxoSmithKline (GSK) medical monitor, places the subject at an unacceptable risk as participant in this trial. Patients with asthma or diabetes are excluded.
A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody at screening.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
GSK2256294GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.	Drug	Cohort 1, Cohort 2, Cohort 3, Cohort 4
PlaceboMatching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).	Drug	Cohort 1, Cohort 2, Cohort 3, Cohort 4

Primary outcome

Safety of single oral doses of GSK2256294 assessed by clinical monitoring of vital signs (Cohort 1).
Time frame: Up to 98 days.
Vital signs include systolic blood pressure, diastolic blood pressure, and pulse rate. Vital signs will be collected with the subject semi-supine and after they have been resting for 5 minutes.
Safety of single oral doses of GSK2256294 assessed by clinical monitoring of vital signs (Cohort 2).
Time frame: Up to 144 days.
Vital signs include systolic blood pressure, diastolic blood pressure, and pulse rate. Vital signs will be collected with the subject semi-supine and after they have been resting for 5 minutes.
Safety of single oral doses of GSK2256294 assessed by clinical monitoring of Electrocardiogram (Cohort 1).
Time frame: Up to 98 days.
12-lead electrocardiograms (ECGs) will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be obtained in the semi-supine position after the subject has been resting for at least 5 minutes.
Safety of single oral doses of GSK2256294 assessed by clinical monitoring of Electrocardiogram (Cohort 2).
Time frame: Up to 144 days.
12-lead electrocardiograms (ECGs) will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be obtained in the semi-supine position after the subject has been resting for at least 5 minutes.
Safety of repeat oral doses of GSK2256294 assessed by clinical monitoring of vital signs (Cohort 3 and 4).
Time frame: Up to 67 days
Vital signs include systolic blood pressure, diastolic blood pressure, and pulse rate. Vital signs will be collected with the subject semi-supine and after they have been resting for 5 minutes.
Safety of repeat oral doses of GSK2256294 assessed by clinical monitoring ECG (Cohort 3 and 4).
Time frame: Up to 67 days.
12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be obtained in the semi-supine position after the subject has been resting for at least 5 minutes.
Safety of single oral doses of GSK2256294 assessed by clinical laboratory assessments (Cohort 1 ).
Time frame: Up to 98 days.
Safety data will include assessments of clinical laboratory tests (hematology, clinical chemistry and urinalysis).
Safety of single oral doses of GSK2256294 assessed by clinical laboratory assessments (Cohort 2).
Time frame: Up to 144 days.
Safety data will include assessments of clinical laboratory tests (hematology, clinical chemistry and urinalysis).
Safety of repeat oral doses of GSK2256294 assessed by clinical laboratory assessments (Cohort 3 and 4).
Time frame: Up to 67 days.
Safety data will include assessments of clinical laboratory tests (hematology, clinical chemistry and urinalysis).
Safety of single oral doses of GSK2256294 assessed by number of participants with adverse events (Cohort 1).
Time frame: Up to 98 days.
Adverse events (AEs) will be recorded from the start of Study Treatment until the follow-up contact.
Safety of single oral doses of GSK2256294 assessed by number of participants with adverse events (Cohort 2).
Time frame: Up to 144 days.
AEs will be recorded from the start of Study Treatment until the follow-up contact.
Safety of repeat oral doses of GSK2256294 assessed by number of participants with adverse events (Cohort 3 and 4).
Time frame: Up to 67 days.
AEs will be recorded from the start of Study Treatment until the follow-up contact.

7 secondary outcomes

Composite of PK parameters following single dose of GSK2256294.
Time frame: PK samples will be collected at pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours post dose in each treatment period.
Composite of PK parameters following repeat doses of GSK2256294.
Time frame: Up to Day 17 in Cohort 3 and 4
Percent inhibition of sEH enzyme activity in whole blood after single oral dose of GSK2256294 as a measure of PD effect.
Time frame: Plasma samples will be collected at pre-dose, 1, 2, 6, 8, 12, 24, 48, and 72 hours post dose in Cohort 1 and 2.
Percent inhibition of sEH enzyme activity and Leukotoxin : leukotoxin-diol ratio in plasma after repeat oral doses of GSK2256294 .
Time frame: Up to Day 17 in Cohort 3 and 4
Exposure-response relationship between the blood concentration of GSK2256294 and sEH enzyme inhibition, leukotoxin : leukotoxin-diol ratio (if data permit) following single dose of GSK2256294.
Time frame: Plasma samples will be collected at pre-dose, 1, 2, 6, 8, 12, 24, 48, and 72 hours post dose in cohort 1 and 2.
Exposure-response relationship between the blood concentration of GSK2256294 and sEH enzyme inhibition, leukotoxin : leukotoxin-diol ratio (if data permit) following repeat doses of GSK2256294.
Time frame: Up to Day 17 in cohort 3 and 4.
Change from baseline forearm blood flow relative to the preceding challenge agent, as measured by venous occlusion plethysmography.
Time frame: Baseline (screening) and Day 1 and Day 14 in Cohort 3 and 4.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2017.
Derived from this study: PubMed 27884766Yang L, Cheriyan J, Gutterman DD, Mayer RJ, Ament Z, Griffin JL, Lazaar AL, Newby DE, Tal-Singer R, Wilkinson IB. Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. Chest. 2017 Mar;151(3):555-563. doi: 10.1016/j.chest.2016.10.058. Epub 2016 Nov 21.
Derived from this study: PubMed 26620151Lazaar AL, Yang L, Boardley RL, Goyal NS, Robertson J, Baldwin SJ, Newby DE, Wilkinson IB, Tal-Singer R, Mayer RJ, Cheriyan J. Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. Br J Clin Pharmacol. 2016 May;81(5):971-9. doi: 10.1111/bcp.12855. Epub 2016 Jan 17.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.Link provided by the sponsor.
Results for study 114068 can be found on the GSK Clinical Study Register.Link provided by the sponsor.
Individual participant dataSharing planned: Yes. Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Related trials for Pulmonary Disease, Chronic Obstructive

Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

GSK Clinical Trials study director

GlaxoSmithKline

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing GSK2256294 in people with Pulmonary Disease, Chronic Obstructive, run by GlaxoSmithKline at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety of single oral doses of GSK2256294 assessed by clinical monitoring of vital signs (Cohort 1). (time frame: Up to 98 days.). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01762774, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2017.